Phase II/III data for mRNA-1273.211 showed superiority against variants of concern to the original Spikevax, but Moderna’s top competitor has questioned the need for multivalent approaches.
The stiff competition between Moderna, Inc. and Pfizer Inc./BioNTech SE on COVID-19 vaccines will likely continue as Moderna has produced positive results for its bivalent vaccine designed to protect against the original strain of the virus as well as variants of concern, while Pfizer/BioNTech develop their own monovalent, Omicron-specific vaccine candidate.
On 19 April, Moderna announced data from one cohort of its Phase II/III study that tested mRNA-1273.211, a bivalent COVID-19...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
